Canada Ophthalmic Drugs Market Forecast 2023-2030

The Canada ophthalmic drugs market growth is set to project a CAGR of 7.39% during the forecast period, 2023-2030. The market growth is accredited to a growing aging population, increasing prevalence of eye disorders, and advancements in research and development.

MARKET INSIGHTS

Canadian research institutions and pharmaceutical companies actively engage in research and development endeavors aimed at discovering and creating innovative treatments for eye diseases. There is a growing emphasis on formulating personalized and precision medicine strategies tailored to meet the unique needs of individual patients. The nation boasts a robust healthcare system that provides access to specialized eye care services. Various facilities, including eye care clinics, ophthalmic hospitals, and private practices, offer an extensive range of services, spanning routine eye examinations to advanced surgical procedures.

Within Canada, Health Canada assumes the responsibility of regulating ophthalmic drugs. Manufacturers are required to comply with Good Manufacturing Practices (GMP) and meet the safety, efficacy, and quality standards established by Health Canada. The regulatory process involves a thorough evaluation of drug submissions, encompassing both new drug submissions (NDS) and abbreviated new drug submissions (ANDS) for generic products. This ensures that ophthalmic drugs fulfill the necessary criteria before being authorized for market distribution.

Nevertheless, the Canadian ophthalmology industry encounters challenges, including the high costs associated with drug development, regulatory approval processes, and limited access to specialized care in remote areas. Tackling these challenges offers opportunities for enhanced collaboration, the implementation of cost-effective solutions, and the integration of telemedicine to enhance accessibility to eye care services.

COMPETITIVE INSIGHTS

Pfizer Inc, Bausch Health Companies Inc, and Johnson & Johnson are among the prominent companies in the market.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 73992

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT - CANADA
2.3. COUNTRY ANALYSIS - CANADA
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
- 2.5.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.6. MAJOR MARKET FINDINGS
- 2.6.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
- 2.6.2. GROWING DEMAND FOR COMBINATION THERAPIES
- 2.6.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
- 2.6.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
- 3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
- 3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
- 3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
- 3.2.1. DELAY IN DRUG APPROVALS
- 3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. GROWING INTEREST IN TOPICAL OPHTHALMIC DRUGS
- 4.1.2. SIGNIFICANT RISE IN NOVEL OPHTHALMIC THERAPEUTICS APPROVALS
4.2. TECHNOLOGY SNAPSHOT
- 4.2.1. BIOLOGICS
- 4.2.2. CELL THERAPY
- 4.2.3. GENE THERAPY
- 4.2.4. DRUG DELIVERY
- 4.2.5. SMALL MOLECULE
- 4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING - CANADA
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK

5. MARKET BY INDICATION

5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
- 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
- 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
- 5.4.3. DIABETIC RETINOPATHY
- 5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS

6. MARKET BY TYPE

6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DOSAGE FORM

7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS

8. MARKET BY THERAPEUTIC CLASS

8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES

9. MARKET BY DISTRIBUTION CHANNEL

9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS

10. COMPETITIVE LANDSCAPE

10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
10.2. COMPANY PROFILES
- 10.2.1. ABBVIE INC
  - 10.2.1.1. COMPANY OVERVIEW
  - 10.2.1.2. PRODUCTS & SERVICES
  - 10.2.1.3. STRENGTHS & CHALLENGES
- 10.2.2. BAUSCH HEALTH COMPANIES INC
  - 10.2.2.1. COMPANY OVERVIEW
  - 10.2.2.2. PRODUCTS & SERVICES
  - 10.2.2.3. STRENGTHS & CHALLENGES
- 10.2.3. JOHNSON & JOHNSON
  - 10.2.3.1. COMPANY OVERVIEW
  - 10.2.3.2. PRODUCTS & SERVICES
  - 10.2.3.3. STRENGTHS & CHALLENGES
- 10.2.4. NOVARTIS AG
  - 10.2.4.1. COMPANY OVERVIEW
  - 10.2.4.2. PRODUCTS & SERVICES
  - 10.2.4.3. STRENGTHS & CHALLENGES
- 10.2.5. PFIZER INC
  - 10.2.5.1. COMPANY OVERVIEW
  - 10.2.5.2. PRODUCTS & SERVICES
  - 10.2.5.3. STRENGTHS & CHALLENGES
- 10.2.6. REGENERON PHARMACEUTICALS INC
  - 10.2.6.1. COMPANY OVERVIEW
  - 10.2.6.2. PRODUCTS & SERVICES
  - 10.2.6.3. STRENGTHS & CHALLENGES
- 10.2.7. SANTEN PHARMACEUTICAL CO LTD
  - 10.2.7.1. COMPANY OVERVIEW
  - 10.2.7.2. PRODUCTS & SERVICES
  - 10.2.7.3. STRENGTHS & CHALLENGES